Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.
about
Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic FibrosisInhaled Antibiotics for Gram-Negative Respiratory InfectionsEvaluation and modification of commercial dry powder inhalers for the aerosolization of a submicrometer excipient enhanced growth (EEG) formulationTargeting aerosol deposition to and within the lung airways using excipient enhanced growthAerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performanceClinical experimentation with aerosol antibiotics: current and future methods of administration.Inhaled antibiotics for lower airway infections.Recent advances in capsule-based dry powder inhaler technology.Development of high efficiency ventilation bag actuated dry powder inhalers.Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial.Advances in device and formulation technologies for pulmonary drug delivery.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Biologic comparison of inhaled insulin formulations: Exubera™ and novel spray-dried engineered particles of dextran-10.Inhalable Spray-Freeze-Dried Powder with L-Leucine that Delivers Particles Independent of Inspiratory Flow Pattern and Inhalation Device.Edge activators and a polycationic polymer enhance the formulation of porous voriconazole nanoagglomerate for the use as a dry powder inhaler.Tackling the increasing complexity of CF care.Characterization of a New High-Dose Dry Powder Inhaler (DPI) Based on a Fluidized Bed Design.Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data.Investigation of the Changes in Aerosolization Behavior Between the Jet-Milled and Spray-Dried Colistin Powders Through Surface Energy Characterization.Development of a high efficiency dry powder inhaler: effects of capsule chamber design and inhaler surface modifications.Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma.Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.Tobramycin for the treatment of bacterial pneumonia in children.Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises.Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.Improving inhaler technique, adherence to therapy and the precision of dosing: major challenges for pulmonary drug delivery.Advances in metered dose inhaler technology: formulation developmentAdvances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product.The PulmoSphere™ platform for pulmonary drug delivery.Orally inhaled fixed-dose combination products for the treatment of asthma and chronic obstructive pulmonary disease: not simple math.Aerosolized antibiotics in cystic fibrosis: an update.Progress towards next-generation therapeutics for cystic fibrosis.Opportunities in respiratory drug delivery.Use of inhaled tobramycin in cystic fibrosis.Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.Clinical pharmacokinetics of inhaled antimicrobials.Long-term safety and efficacy of tobramycin in the management of cystic fibrosis.Devices for dry powder drug delivery to the lung.Industry guidance for the selection of a delivery system for the development of novel respiratory products.
P2860
Q26829604-0EEFA012-6A5A-4132-95FA-4132F68B70DAQ28386160-33AD3F59-2A46-43FD-B0B3-C7BC2E5ADC07Q28387314-43638EB1-2C55-4CF9-B452-ABD12ED9A9E3Q28390979-16740A0D-A0A3-4EC0-BF5F-5A2EEF4EB9B1Q28394991-C05659AA-7691-4F9D-8B3D-E843A9EC4D84Q30448377-2319C1D2-039E-42C4-9D8F-7C7A72A7EBC2Q33640488-B44BB78D-BC44-422A-86E9-1D383B775ECFQ33711473-FCA546D9-21C9-4DA3-8FE1-FDE223630B16Q33732483-C0F779ED-03FD-4D9B-AF13-992BBEFD400BQ33861076-EDCD5308-B297-4064-A36B-15B4FF9E2870Q33962567-CD215033-0ACE-418C-8D28-2B9B662D8ADCQ34297656-087162B7-11A1-4CEA-B8A1-FE5C729D1586Q34577401-A5342F8B-BF2F-476E-8555-5A8835632DBFQ35862967-B0E4F559-1A66-4FD5-8FB4-E9248F28C12CQ35922737-39633977-3DE5-4FB0-94A0-C8CDA78804A8Q36034488-816F840C-58F8-4DEE-9089-A0DA35E2735DQ36200226-D7964095-8583-4EF1-AE19-FE6D7DA1F5A5Q36368310-BD31AE63-8B88-4FE2-959B-15F53E395EF9Q36642374-7F7E6995-CB9E-48FE-B042-45BAF57A9EF6Q37625308-6F2009E1-0F3A-45B2-B7C8-2DABD3D481DAQ37937562-B0E94896-BC5B-4EAD-B8CF-29247DED7BF2Q37940005-95032457-2747-4E23-B4A2-BB80D57E22B8Q37980230-915E2654-B1AF-49D7-A51E-73A2B63AC999Q38033610-FB899837-CDA5-4BCF-BFE0-7F42801F5E2DQ38037076-0324A87E-B57F-40F7-B3B7-3BABEF473F4EQ38160206-7BF47E78-564F-4ECD-B36D-AD4615627C51Q38175421-603AE49D-F24A-414F-A13C-192793B3A83BQ38180975-D23BC045-71A1-4968-8174-30D76C83BAF2Q38185862-C3B41E47-62F7-45A9-B939-CEE1E405C9DFQ38193170-8AB356F6-AC12-4363-835D-58A2F47B87B5Q38193172-846E254B-50FD-4043-95BC-FF738DF972B2Q38212537-EF28E553-20AF-4743-AF45-C92AAAC74D34Q38234646-434BA8AB-E3C0-46B6-9BCE-D2C57B650C0DQ38297120-237E0C7E-B9E8-4D21-9079-6E08F825BA23Q38332222-4973992A-70D7-4AB7-A6AA-17BBD960EBCDQ38358856-108FEFB8-A856-4318-B949-FED7B264EA39Q38367260-CA0E4CC1-5424-43E7-8BC5-4C0C4B1DF12FQ38384994-A88ECEA4-6E63-4EA1-BD09-6F06A154B42EQ38474246-5742629B-4C99-431B-ADC4-DDF482B24313Q38525610-70003478-B763-4C0B-B3AA-A823F0BBBC60
P2860
Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of an inhaled dry- ...... using PulmoSphere™ technology.
@en
Development of an inhaled dry- ...... using PulmoSphere™ technology.
@nl
type
label
Development of an inhaled dry- ...... using PulmoSphere™ technology.
@en
Development of an inhaled dry- ...... using PulmoSphere™ technology.
@nl
prefLabel
Development of an inhaled dry- ...... using PulmoSphere™ technology.
@en
Development of an inhaled dry- ...... using PulmoSphere™ technology.
@nl
P2093
P2860
P356
P1476
Development of an inhaled dry- ...... using PulmoSphere™ technology.
@en
P2093
David E Geller
Jeffry Weers
Silvia Heuerding
P2860
P304
P356
10.1089/JAMP.2010.0855
P577
2011-03-11T00:00:00Z